Can a patient with atrial fibrillation safely take Viagra (sildenafil) or Cialis (tadalafil)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Patients with Atrial Fibrillation Safely Use Viagra or Cialis?

Yes, patients with atrial fibrillation can safely take Viagra (sildenafil) or Cialis (tadalafil), provided they are not taking nitrates and their cardiovascular status is stable enough for sexual activity. The primary concern is not the atrial fibrillation itself, but rather the overall cardiovascular risk profile and potential drug interactions.

Key Safety Considerations

Absolute Contraindications

The most critical safety issue is nitrate use. PDE5 inhibitors (sildenafil, tadalafil) are absolutely contraindicated in patients taking any form of organic nitrates due to severe hypotension risk 1. For sildenafil and vardenafil, avoid nitrates for ≥24 hours after use; for tadalafil, avoid for ≥48 hours due to its longer half-life (17.5 hours) 2.

Cardiovascular Risk Stratification

Before prescribing PDE5 inhibitors to AF patients, assess their cardiovascular risk using the Princeton Consensus framework 3, 4:

Low-Risk Patients (Safe for PDE5 Inhibitors):

  • Controlled hypertension
  • Mild, stable angina
  • Post-successful coronary revascularization (>6-8 weeks)
  • Uncomplicated past MI (>6-8 weeks)
  • Mild valvular disease
  • NYHA Class I heart failure

Intermediate-Risk Patients (Require Exercise Testing):

  • ≥3 major CAD risk factors
  • Moderate, stable angina
  • Recent MI (2-6 weeks ago)
  • NYHA Class II heart failure

These patients should undergo exercise stress testing. If they can achieve 4-5 METs (equivalent to the Bruce protocol) without symptoms, ischemia, or blood pressure drop, they can be reclassified as low-risk 3, 4.

High-Risk Patients (Defer Treatment):

  • MI within last 90 days
  • Unstable angina
  • NYHA Class III-IV heart failure
  • Uncontrolled arrhythmias
  • Uncontrolled hypertension or hypotension (<90/50 mmHg)
  • Stroke within last 6 months

1

Atrial Fibrillation-Specific Considerations

The presence of atrial fibrillation itself does not contraindicate PDE5 inhibitor use. The AF guidelines 5, 6 focus on rate control, rhythm control, and anticoagulation but do not specifically prohibit PDE5 inhibitors. In fact, emerging research suggests sildenafil may actually decrease AF susceptibility by increasing atrial effective refractory period and atrial wavelength 7.

Important Caveats

Drug Interactions with AF Medications:

  • Beta-blockers, calcium channel blockers (diltiazem, verapamil), and digoxin used for rate control in AF 5 do not have absolute contraindications with PDE5 inhibitors
  • However, be cautious with alpha-blockers if used concomitantly, as this can cause symptomatic hypotension 8
  • Tadalafil provides continuous plasma levels when used daily, requiring careful consideration of drug interactions 1

Anticoagulation Status:

  • Most AF patients require anticoagulation 5. This does not contraindicate PDE5 inhibitors but requires awareness of bleeding risk if the patient has other conditions predisposing to priapism 1

Hemodynamic Effects

PDE5 inhibitors cause mild vasodilation with modest blood pressure reductions. Tadalafil 20 mg causes mean decreases of 1.6/0.8 mmHg in healthy subjects 1. Studies in cardiovascular disease patients show sildenafil does not significantly affect exercise-induced hemodynamic changes or increase ventricular arrhythmias 9, 8. The cardiovascular metabolic cost of sexual activity is approximately 3-5 METs, which most stable AF patients can tolerate 3, 10.

Practical Algorithm

  1. Confirm no nitrate use (absolute contraindication)
  2. Assess cardiovascular risk using Princeton criteria
  3. If low-risk: Prescribe PDE5 inhibitor with standard precautions
  4. If intermediate-risk: Perform exercise stress test to 4-5 METs
    • If negative: Proceed with PDE5 inhibitor
    • If positive: Defer until cardiac condition stabilized
  5. If high-risk: Refer to cardiology; defer PDE5 inhibitor until stabilized
  6. Ensure adequate rate control of AF before initiating treatment 5
  7. Counsel patient to stop sexual activity and seek emergency care if chest pain develops 2, 1

Common Pitfalls

  • Failing to ask about nitrate use, including as-needed sublingual nitroglycerin
  • Overlooking uncontrolled hypertension in AF patients on multiple medications
  • Not considering the longer half-life of tadalafil when counseling about nitrate avoidance
  • Assuming AF itself is a contraindication when the real concern is overall cardiovascular stability

The evidence demonstrates that with appropriate patient selection and attention to contraindications—particularly nitrate use—PDE5 inhibitors can be safely prescribed to patients with atrial fibrillation 9, 8, 10.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.